Literature DB >> 11919108

Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research.

P A Brogan1, A Bose, D Burgner, D Shingadia, R Tulloh, C Michie, N Klein, R Booy, M Levin, M J Dillon.   

Abstract

This article proposes a clinical guideline for the diagnosis and treatment of Kawasaki disease in the UK based on the best available evidence to date, and highlights areas of practice where evidence is anecdotal or based on retrospective data. Future research as proposed by the London Kawasaki Disease Research Group is outlined, and clinicians are invited to prospectively enroll their suspected cases into this collaborative research project.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11919108      PMCID： PMC1719139          DOI： 10.1136/adc.86.4.286

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


  25 in total

1.  Kawasaki Disease.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-06

2.  Erythropoiesis is distinct at each stage of ontogeny.

Authors:  R S Weinberg; L Y He; B P Alter
Journal:  Pediatr Res       Date:  1992-02       Impact factor: 3.756

3.  In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant.

Authors:  V Combes; A C Simon; G E Grau; D Arnoux; L Camoin; F Sabatier; M Mutin; M Sanmarco; J Sampol; F Dignat-George
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

4.  [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].

Authors:  T Kawasaki
Journal:  Arerugi       Date:  1967-03

Review 5.  Animal models of infection-mediated vasculitis: implications for human disease.

Authors:  A J Dal Canto; H W Virgin
Journal:  Int J Cardiol       Date:  2000-08-31       Impact factor: 4.164

6.  Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin.

Authors:  R C Dale; M A Saleem; S Daw; M J Dillon
Journal:  J Pediatr       Date:  2000-11       Impact factor: 4.406

7.  Platelet glycoprotein IIb/IIIa receptor blockade therapy for large coronary aneurysms and thrombi in Kawasaki disease.

Authors:  S P Etheridge; L Y Tani; L L Minich; J R Revenaugh
Journal:  Cathet Cardiovasc Diagn       Date:  1998-11

8.  Characterization of the T-cell receptor V-beta repertoire in Kawasaki disease.

Authors:  L Mancia; J Wahlström; B Schiller; L Chini; G Elinder; P D'Argenio; D Gigliotti; H Wigzell; P Rossi; J Grunewald
Journal:  Scand J Immunol       Date:  1998-10       Impact factor: 3.487

9.  Management of Kawasaki disease in the British Isles.

Authors:  R Dhillon; L Newton; P T Rudd; S M Hall
Journal:  Arch Dis Child       Date:  1993-12       Impact factor: 3.791

10.  The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment.

Authors:  K Durongpisitkul; V J Gururaj; J M Park; C F Martin
Journal:  Pediatrics       Date:  1995-12       Impact factor: 7.124
View more
  48 in total

Review 1.  Update on the treatment of Kawasaki disease in childhood.

Authors:  Robert P Sundel
Journal:  Curr Rheumatol Rep       Date:  2002-12       Impact factor: 4.592

2.  Coronary risk factors in Kawasaki disease treated with additional gammaglobulin.

Authors:  M Miura; H Ohki; T Tsuchihashi; H Yamagishi; Y Katada; K Yamada; Y Yamashita; A Sugaya; O Komiyama; H Shiro
Journal:  Arch Dis Child       Date:  2004-08       Impact factor: 3.791

3.  [Fever, bilateral conjunctivitis, cervical lymphadenopathy, lacquered lips and rash].

Authors:  S Cantemir; S Flüshöh; G Koch; A Laubert
Journal:  HNO       Date:  2004-04       Impact factor: 1.284

4.  Kawasaki syndrome during pregnancy: a case report and literature review.

Authors:  Eleftheria Lefkou; Ula Mahadeva; Andy Jones; Jane Hancock; Beverley J Hunt
Journal:  Obstet Med       Date:  2008-09-01

5.  Reevaluation of the efficacy of intravenous gammaglobulin in the prevention and treatment of coronary artery lesion in Kawasaki disease.

Authors:  Lijun Qin; Mweri Tobbi Saumu; Hongwei Wang; Hong Shi; Xiufen Hu; Peixuan Cheng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

6.  Comparison of high-dose versus low-dose aspirin in the management of Kawasaki disease.

Authors:  Aliakbar Rahbarimanesh; Mozhgan Taghavi-Goodarzi; Payam Mohammadinejad; Javad Zoughi; Jalalaldin Amiri; Kasra Moridpour
Journal:  Indian J Pediatr       Date:  2014-04-08       Impact factor: 1.967

7.  Relapse of nephrotic syndrome triggered by Kawasaki disease.

Authors:  Ryo Maeda; Yukihiko Kawasaki; Shigeo Suzuki; Shinichiro Ohara; Suyama Kazuhide; Mitsuaki Hosoya
Journal:  CEN Case Rep       Date:  2017-11-15

8.  Kawasaki disease in ghana: case reports from Korle Bu teaching hospital.

Authors:  E V Badoe; J Neequaye; J O Oliver-Commey; J Amoah; A Osafo; I Aryee; M Y Nyarko
Journal:  Ghana Med J       Date:  2011-03

9.  Pelviureteric junction obstruction as sequelae of Kawasaki disease.

Authors:  R Subramaniam; T Lama; C Y Chong
Journal:  Pediatr Surg Int       Date:  2004-07-10       Impact factor: 1.827

10.  Long-term follow-up of acute changes in coronary artery diameter caused by Kawasaki disease: risk factors for development of stenotic lesions.

Authors:  Fabienne Mueller; Walter Knirsch; Paul Harpes; René Prêtre; Emanuela Valsangiacomo Buechel; Oliver Kretschmar
Journal:  Clin Res Cardiol       Date:  2009-06-05       Impact factor: 5.460
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.